Trial reportWorld journal of gastroenterology2011
Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients.
Trial report in World journal of gastroenterology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed, 7 syntheses or guidelines pooled it, 191 citations in OpenAlex.
- Role of Vitamin D Supplementation in Chronic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Nutrition reviews · 2025Pooled it
- Vitamin D supplementation for chronic liver diseases in adults.The Cochrane database of systematic reviews · 2021Pooled it
- A Rapid Advice Guideline for the Prevention of Novel Coronavirus Through Nutritional Intervention.Current nutrition reports · 2020Guideline
- Vitamin D supplementation for chronic liver diseases in adults.The Cochrane database of systematic reviews · 2017Pooled it
- Vitamin D supplementation for prevention of mortality in adults.The Cochrane database of systematic reviews · 2014Pooled it
- Association between vitamin D and hepatitis C virus infection: a meta-analysis.World journal of gastroenterology · 2013Pooled it
- Enhancing immunity in viral infections, with special emphasis on COVID-19: A review.Diabetes & metabolic syndromePooled it
- Effects of vitamin D supplements in patients with chronic hepatitis C: a randomized, multi-center, open label study.The Korean journal of internal medicine · 2020Trial
- Efficacy of vitamin DTrials · 2017Trial
- Vitamin D Status and Virologic Response to HCV Therapy in the HALT-C and VIRAHEP-C Trials.PloS one · 2016Trial
- Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study.World journal of gastroenterology · 2015Trial
- Vitamin D status and viral response to therapy in hepatitis C infected children.World journal of gastroenterology · 2015Trial
- Trial
- Trial
- The Modulatory Role of Vitamin D in the Molecular Mechanisms of Sepsis and Infections with Focus on Viral Pathogenesis: A Narrative Review.Pathogens (Basel, Switzerland) · 2026Review
- Immune Modulatory Effects of Vitamin D on Herpesvirus Infections.International journal of molecular sciences · 2025Review
- The Role of Vitamin D and Vitamin D Binding Protein in Chronic Liver Diseases.International journal of molecular sciences · 2022Review
- Article
- Vitamin D-VDR Novel Anti-Inflammatory Molecules-New Insights into Their Effects on Liver Diseases.International journal of molecular sciences · 2022Review
- Metabolic aspects of hepatitis C virus.World journal of gastroenterology · 2022Review
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo determine whether adding vitamin D, a potent immunomodulator, improves the hepatitis C virus (HCV) response to antiviral therapy.
methodsSeventy-two consecutive patients with chronic HCV genotype 1 were randomized into two groups: the treatment group (n = 36, 50% male, mean age 47 ± 11 years) received Peg-α-2b interferon (1.5 μg/kg per week) plus ribavirin (1000-1200 mg/d) together with vitamin D3 (2000 IU/d, target serum level > 32 ng/mL), and the control group (n = 36, 60% male, mean age 49 ± 7 years) received identical therapy without vitamin D. HCV-RNA was assessed by real-time polymerase chain reaction (sensitivity, 10 IU/mL). The sustained virologic response (SVR) was defined as undetectable HCV-RNA at 24 wk post-treatment.
resultsClinical characteristics were similar in both groups. The treatment group had a higher mean body mass index (27 ± 4 kg/m² vs 24 ± 3 kg/m²; P < 0.01), viral load (50% vs 42%, P < 0.01), and fibrosis score (> F2: 42% vs 19%, P < 0.001) than the controls. At week 4, 16 (44%) treated patients and 6 (17%) controls were HCV-RNA negative (P < 0.001). At week 12, 34 (94%) treated patients and 17 (48%) controls were HCV-RNA negative (P < 0.001). At 24 wk post-treatment (SVR), 31 (86%) treated patients and 15 (42%) controls were HCV-RNA negative (P < 0.001). Viral load, advanced fibrosis and vitamin D supplementation were strongly and independently associated with SVR (multivariate analysis). Adverse events were mild and typical of Peg-α-2b/ribavirin.
conclusionAdding vitamin D to conventional Peg-α-2b/ribavirin therapy for treatment-naïve patients with chronic HCV genotype 1 infection significantly improves the viral response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.